

05-16-06



EL 983153681US

PH7513 US -NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 983153681 US
Express Mail Label Number

May 15, 2006
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
DONALD PINTO, ET AL.
APPLICATION NO: 10/801,519
FILED: 03/16/2004

ART UNIT: 1626
EXAMINER: FREISTEIN, ANDREW B

FOR: **LINEAR CHAIN SUBSTITUTED MONOCYCLIC AND BICYCLIC
DERIVATIVES AS FACTOR Xa INHIBITORS**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:


Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000


Jing G. Sun, Ph.D.
Agent for Applicant
Reg. No. 45,914
Phone: 609-252-3791
Date: May 15, 2006



PH7513 US - NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 983153681 US
Express Mail Label Number

May 15, 2006
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
DONALD PINTO, ET AL.
APPLICATION NO: 10/801,519
FILED: 03/16/2004

ART UNIT: 1626
EXAMINER: FREISTEIN, ANDREW B

FOR: **LINEAR CHAIN SUBSTITUTED MONOCYCLIC AND BICYCLIC
DERIVATIVES AS FACTOR Xa INHIBITORS**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s) and charge the appropriate fee under §1.17 (p) to Deposit Account 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,



Jing G. Sun, Ph.D.
Agent for Applicant
Reg. No. 45,914
Phone: 609-252-3791
Date: May 15, 2006

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000

05/18/2006 08543-4000 10881519
Princeton, NJ 08543-4000
01 FC:1806 180.00 DA



MAY 15 2006

Substitute for form 1449/PTO

PTO/SB/08B (8/03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT(S)**

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/801,519
Filing Date	03/16/2004
First Named Inventor	DONALD PINTO
Art Unit	1626
Examiner Name	FREISTEIN, ANDREW B
Attorney Docket Number	PH 7513 NP

Sheet

1

of

1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	AA	Bauer, K.A., "Fondaparinux: a new synthetic and selective inhibitor of Factor Xa", Best Practice & Research Clinical Haematology, Vol. 17, No: 1, pp. 89-104, 2004.	
	AB	Gresele et al., "Novel approaches to the treatment of thrombosis", TRENDS in Pharmacological Sciences, Vol. 23, No. 1, pp. 25-32, Jan 2002.	
	AC	Linkins et al., "New Anticoagulants", Seminars in Thrombosis and Hemostasis, Vol. 29, No. 6, pp. 619-631, 2003.	
	AD	Rauch et al., "Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences", Annals of Internal Medicine, Vol. 134, No. 3., pp. 224-238, 6 February 2001.	
	AE	Ruef et al., "New antithrombotic drugs on the horizon", Expert Opin. Investig. Drugs, Vol. 12, No. 5, pp. 781-797, 2003.	
	AF	Weitz et al., "Thrombophilia and New Anticoagulant Drugs", Hematology, pp. 424-438, 2004.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant